Show simple item record

dc.contributor.authorShandilya, Shivender
dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorSadowski, Andrew
dc.contributor.authorMonir, Ejemel
dc.contributor.authorSchiller, Zachary A.
dc.contributor.authorThomas, William D. Jr.
dc.contributor.authorKlempner, Mark S.
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorWang, Yang
dc.date2022-08-11T08:10:52.000
dc.date.accessioned2022-08-23T17:23:00Z
dc.date.available2022-08-23T17:23:00Z
dc.date.issued2016-11-16
dc.date.submitted2017-02-17
dc.identifier.citation<p>J Mol Recognit. 2016 Nov 16. doi: 10.1002/jmr.2595. <a href="https://doi.org/10.1002/jmr.2595">Link to article on publisher's site</a></p>
dc.identifier.issn0952-3499 (Linking)
dc.identifier.doi10.1002/jmr.2595
dc.identifier.pmid27859766
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48867
dc.description.abstractThe murine monoclonal antibody LA-2 recognizes a clinically protective epitope on outer surface protein (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in North America. Human antibody equivalence to LA-2 is the best serologic correlate of protective antibody responses following OspA vaccination. Understanding the structural and functional basis of the LA-2 protective epitope is important for developing OspA-based vaccines and discovering prophylactic antibodies against Lyme disease. Here, we present a detailed structure-based analysis of the LA-2/OspA interaction interface and identification of residues mediating antibody recognition. Mutations were introduced into both OspA and LA-2 on the basis of computational predictions on the crystal structure of the complex and experimentally tested for in vitro binding and borreliacidal activity. We find that Y32 and H49 on the LA-2 light chain, N52 on the LA-2 heavy chain and residues A208, N228 and N251 on OspA were the key constituents of OspA/LA-2 interface. These results reveal specific residues that may be exploited to modulate recognition of the protective epitope of OspA and have implications for developing prophylactic passive antibodies.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27859766&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383521/
dc.subjectantibody
dc.subjectLyme disease
dc.subjectmutations
dc.subjectprotein-protein
dc.subjectstructural analysis
dc.subjectmolecular interactions
dc.subjectvaccine design
dc.subjectprotein structure
dc.subjectUMCCTS funding
dc.subjectBacterial Infections and Mycoses
dc.subjectBiochemistry
dc.subjectImmunoprophylaxis and Therapy
dc.subjectMedicinal Chemistry and Pharmaceutics
dc.subjectMedicinal-Pharmaceutical Chemistry
dc.subjectMolecular Biology
dc.subjectStructural Biology
dc.titleStructural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions
dc.typeJournal Article
dc.source.journaltitleJournal of molecular recognition : JMR
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/schiffer/14
dc.identifier.contextkey9705342
html.description.abstract<p>The murine monoclonal antibody LA-2 recognizes a clinically protective epitope on outer surface protein (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in North America. Human antibody equivalence to LA-2 is the best serologic correlate of protective antibody responses following OspA vaccination. Understanding the structural and functional basis of the LA-2 protective epitope is important for developing OspA-based vaccines and discovering prophylactic antibodies against Lyme disease. Here, we present a detailed structure-based analysis of the LA-2/OspA interaction interface and identification of residues mediating antibody recognition. Mutations were introduced into both OspA and LA-2 on the basis of computational predictions on the crystal structure of the complex and experimentally tested for in vitro binding and borreliacidal activity. We find that Y32 and H49 on the LA-2 light chain, N52 on the LA-2 heavy chain and residues A208, N228 and N251 on OspA were the key constituents of OspA/LA-2 interface. These results reveal specific residues that may be exploited to modulate recognition of the protective epitope of OspA and have implications for developing prophylactic passive antibodies.</p>
dc.identifier.submissionpathschiffer/14
dc.contributor.departmentMassBiologics
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology


This item appears in the following Collection(s)

Show simple item record